CYTK - Cytokinetics Inc
Cytokinetics Inc Logo

CYTK - Cytokinetics Inc

https://www.cytokinetics.com
Buy Momentum: Bearish
Recent News
Powered by Alpha Vantage
Neutral
Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine - Cytokinetics ( NASDAQ:CYTK )
Benzinga • 2 weeks, 2 days ago • score: 0.06
Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol Primary Endpoint Result Consistent Across All Prespecified Subgroups Company to Host Investor Event and Webcast Tuesday September 2, 2025, at 8:00 AM Eastern Time
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)

Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering, developing and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is headquartered in South San Francisco, California.

52W High
$59.39
52W Low
$29.31
MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
0.62
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-15.82
EV/Revenue (<3 favorable)
73.98
P/S (TTM) (<3 favorable)
73.98
P/B (<3 favorable)
60.31
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
0.69%
Institutions (25–75% balanced)
117.99%
Shares Outstanding
119,657,000
Float
119,102,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
85,738,000
Gross Profit (TTM)
-304,897,984
EPS (TTM)
-5.12
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-1.67%
ROE (TTM) (>15% strong)
-5.72%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
267.15
Momentum
Bearish momentum
Value
5.1267
Previous
5.2801
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025